The company will use the capital to support a China Phase III trial of APL-1202, a repurposed oral inhibitor of MetAP2.
December 27, 2017 -- Asieris Pharmaceuticals, a China company focused on cancer, raised “over” $15 million in a B round. The company will use the capital to support a China Phase III trial of APL-1202, a repurposed oral inhibitor of MetAP2. MetAP2 is a 50-year-old wide spectrum antibiotic that recently has been shown to have an anti-angiogenesis effect. It will be tested as a treatment for patients with relapsed non-muscle invasive bladder cancer (NMIBC). The B round was led by Lapam Capital.
